For an Executive Summary of this report please contact ediz.ibrahim@visiongain.com (+44 (0)20 7549 9976) or refer to our website http://www.visiongain.com/Report/1232/Cell-Based-Assays-World-Industry-and-Market-Prospects-2014-2024

1. ©notice
This material is copyright by visiongain. It is against the law to reproduce any of this material without the prior written agreement of vision-
gain. You cannot photocopy, fax, download to database or duplicate in any other way any of the material contained in this report. Each pur-
chase and single copy is for personal use only.
Cell-Based Assays:
World Industry and Market Prospects
2014-2024

2. www.visiongain.com
Contents
1.1 Introducing This New Study
1.2 Cell-Based Assays: World Market Overview to 2024
1.3 Chapter Outlines
1.4 Research and Analysis Methods
1.5 Scope of this Report
2.1 What are Cell-Based Assays?
2.2 Drug Discovery and Development
2.3 Cell-Based Assays Offer Advantages Over Other Assay Types
2.4 2D vs. 3D Cell-Based Assays
2.5 Assay Detection Technology
2.6 Drug Testing Using High-Throughput Screening (HTS)
2.7 Cells Used in Cell-Based Assays
2.7.1 Stem Cells Offer Vast Potential for Drug Screening
3.1 Overview of the World Cell-Based Assays Market in 2013
3.2 Market Projections for Cell-Based Assays, 2014-2024
3.3 Cell-Based Assays: Market Segmentation, 2013
3.3.1 Leading Cell-Based Assays Products. 2014
3. Cell-Based Assays: World Market 2014-2024
2. Introduction to Cell-Based Assays and Applications
1. Executive Summary

3. www.visiongain.com
Contents
3.3.2 The Three Main Categories of Cell-Based Assays Products
3.3.2.1 Equipment to Conduct Cell-Based Assays
3.3.2.2 Disposables Necessary to Perform Cell-Based Assays
3.3.2.3 Consumables Forming the Basis of Cell-Based Assays
3.4 Outsourcing Cell-Based Assays Services
3.4.1 Cell-Based Assay Services: Submarket Revenue Forecast, 2014-2024
3.5 Cell-Based Assays Market Applications
3.5.1 Cell-Based Assays in Drug Discovery Constitute 70% of the Market
3.5.2 ADME-Toxicity Screening (Absorption, Distribution, Metabolism and Excretion)
3.5.3 Basic Research Forms Foundation of Technological Developments
3.6 Total Global R&D Spending Reaches $5.4 Trillion in 2013
3.6.1 Pharma R&D Spending Worth $103bn in 2013
3.6.2 Cell-Based Assays Constitute 3.4% of Pharma R&D Spending
3.6.3 Cell-Based Assays Market: Drivers and Restraints 2014-2024
4.1 Regional Breakdown of the World Cell-Based Assays Market, 2013
4.2 World Cell-Based Assays Market: Regional Forecast 2014-2024
4.3 The US Forms the World’s Largest Cell-Based Assays Market
4.4 The Cell-Based Assays Market in the Five Leading European National Markets, 2014-2024
4.4.1 Market Projections for the Leading EU Countries, 2014-2024
4.4.2 EU Breakdown by Country, 2013
4.4.3 Market Projection for the EU Countries, Regional Breakdown 2014-2024
4.4.4 Germany Has a Strong Drug Discovery Base
4. Leading National Markets for Cell Assays, 2014-2024

4. www.visiongain.com
Contents
4.4.5 France’s Drug Discovery Market at Risk
4.4.6 UK Government Promises More Investment in Science Innovation
4.4.7 The Spanish Market Showing Signs of Economic Recovery
4.4.8 Foreign Pharma Giants Dominate the Italian Market
4.5 Japan Has the World’s Second Largest Pharma Market
4.6 The Cell-Based Assays Market in Emerging Countries, Brazil, Russia, India, China (BRIC)
4.6.1 Breakdown of BRIC Nations by Country, 2013
4.6.2 Market Projections for BRIC Countries, 2014-2024
4.6.3 Brazil Flourishing in R&D Spending
4.6.4 Russian Government Invests $4bn in Pharma Industry
4.6.5 Pharma Giants Setting up in India to Reduce Costs
4.6.6 China’s Rapidly Growing Pharmaceutical Market
5.1 Leading Contract Research Organisations (CROs), 2014
5.1.1 Covance Continues to Dominate the CROs
5.1.2 Charles River Laboratories: Large Player in Early-Stage Drug Development
5.1.3 SGS Offers Specialist Services
5.1.4 Pharmaceutical Product Development (PPD) Recognised for Excellence
5.2 Specialist CROs and Service Companies
5.2.1 Fluofarma’s Specialists in High Content Analysis
5.2.2 Marin Biologic Laboratories Offers Pre-clinical Contract Laboratory Services
5.2.3 MD Biosciences Focuses on Inflammatory, Cardiovascular and Neurological Diseases
5.2.4 ReachBio Shows Primary Cells Are Far More Beneficial
5. Leading Companies in the Cell-Based Assays Market 2014

5. www.visiongain.com
Contents
5.2.5 Cell Assay Innovations (CAI) Develop ClariCELL
5.2.6 ProQinase Specialise in Cancer Drug Discovery
5.3 Cell-Based Assays: Product Suppliers
5.3.1 Beckman Coulter: A Leading Diagnostics Company
5.3.2 Sigma-Aldrich: A Principal Contributor to the Life Science Industry
5.3.3 Thermo Fisher Scientific: The World Leader in Serving Science
5.3.3.1 Life Technologies Corporation Acquired by Thermo Fisher Scientific
5.3.4 GE Healthcare Now Offer Stem Cell Models
5.3.5 Promega: A Leading Life Science Product Manufacturer
5.3.6 BD Biosciences Spans Over 50 Countries Worldwide
5.3.7 DiscoveRx Corporation Launch Oncology and Inflammation Primary Cell-Based
Platforms
5.3.8 BioVision First to Bring a Cholesterol Detection Cell-Based Assay to the Market
5.3.9 Cisbio Bioassays Partner Up With Pharma Giants, Molecular Devices & Tecan
5.3.10 Cell Biolabs: CytoSelect Platform Allows Fully Quantitative Data
5.3.11 Merck Millipore’s Miniaturised Flow Cytometer Awarded Prize by R&D Magazine
5.3.12 PerkinElmer: A Leading Provider of Technology
5.3.13 BioTek: Specialists of Microplate Instrumentation
6.1 3D Systems: The Next Generation of Cell Systems
6.2 Toxicity Testing: Animals or Cells?
6.3 Outsourcing Becoming a Phenomenon
6.4 Primary Cells Offer More Potential
6. Cell-Based Assay Technology and Future Outlook, 2014-2024

6. www.visiongain.com
Contents
6.5 Stem Cells: Tricky Business
6.5.1 Stem Cells in Cell-Based Assays Remain Promising
6.5.2 Many Companies Now Offer Stem Cell Products for the Cell-Based Assay Market
6.5.2.1 STEMCELL Technologies Offer Both iPSCs and ESCs
6.5.3 OncoMed Pharmaceuticals Targeting Cancer Stem Cells
6.6 G-Protein Coupled Receptors (GPCRs)
6.6.1 GPCRs in Cell-Based Assays
6.6.2 Allosteric GPCRs Provide a New Approach
6.7 A Growing Demand for Miniaturisation and Automation
6.8 The Trend towards Robotic Systems
6.9 Microfluidics Can Mimic the In Vivo Environment
6.10 Multiplexing Improves Efficiency of Cell-Based Assays
6.11 Detection Methods in Cell-Based Assays
6.12 High-Content Screening (HCS): A Well Established Tool
6.12.1 Label-Free Systems: A Growing Trend
7.1 SWOT Analysis of the Cell-Based Assays Market
7.1.1 Strengths and Weaknesses of the Cell-Based Assays Market in 2014-2024
7.1.2 Opportunities and Threats in the Cell-Based Assay Market, 2014-2024
7.2 STEP Analysis of the Cell-Based Assays Market
7.2.1 Social Developments: Ethical Alternatives to Animal Testing
7.2.2 A High Demand for Technological Advances
7.2.3 Economic Pressures: Budgetary Restraints
7. Qualitative Analysis of the Cell-Based Assays Market, 2014-2024

7. www.visiongain.com
Contents
7.2.4 Political Issues: Stem Cell Controversy
8.1 Interview with Mr Rob Chaney, General Manager and COO, ReachBio LLC, Seattle, USA
8.1.1 Cell-Based Assays Show Great Potential in Drug Discovery
8.1.2 ReachBio Offer Extensive Cell-Based Assay Services
8.1.3 Why Native Are Cells the Preferential Choice
8.1.4 The Expansion of 3D Systems
8.1.5 Future Projections for Cell-Based Assays
8.2 Interview with Dr Deborah Moshinsky, Founder and President of Cell Assay Innovations,
Massachusetts, USA
8.2.1 Cell-Based Assays are Resource Intensive
8.2.2 Cell Assay Innovation’s ClariCELL Technology
8.2.3 The Cell-Based Assays Market is Vast and Diverse
8.3 Interview with Dr Peter Banks, Scientific Director, BioTek Instruments, Vermont, USA
8.3.1 The Dynamic Cell-Based Assays Market
8.3.2 BioTek’s Leading Technology: Cytation™ 3 Cell Imaging Reader
8.3.3 Pluripotent Stem Cells Offer Technological and Commercial Potential
9.1 The World Cell-Based Assays Market: Predictions to 2024
9.2 Which Nation will Dominate the Market in 2024?
9.3 The Future of the Cell-Based Assays Industry and Market
9. Conclusions
8. Research Interviews from Our Survey

8. www.visiongain.com
Contents
About Visiongain’s Bespoke Research Service
Appendix A: About Visiongain
Appendix B: Visiongain Report Evaluation Form
Appendices

9. www.visiongain.com Page 45
Cell-Based Assays: World Industry
and Market Prospects 2014-2024
3.6.1 Pharma R&D Spending Worth $103bn in 2013
2013 saw the global pharmaceutical industry spend $102.91bn on research and development
(R&D), a 2.4% decrease from 2012. Despite the global stringent healthcare budgeting since the
economic downturn, the pharma and biotech industries will continue to grow at a modest rate.
Table 3.10 and Figure 3.11 show visiongain’s predictions for the pharma R&D spending during the
forecast period 2013-2024. The first half of the forecast period will see a modest growth, with a 5-
year CAGR of 1.4%, reaching revenues of $110.31bn by 2018. This is primarily due to healthcare
budgeting constraints faced by the leading developed countries (US, EU and Japan). Furthermore,
a reduced number of new drug approvals in developed markets over the past two decades; the
declining productivity of pharmaceutical R&D, combined with fewer resources available for Big
Pharma and lower funding from venture capital and private equity firms for small biotechnology
companies, mean that growth in R&D spending has reduced significantly in the last two decades.
This slow growth is expected to continue through to the next 10 years. The pharmerging countries,
on the other hand, will continue to significantly increase R&D expenditure, primarily owing to their
Figure 3.10 Main R&D Spending Subsectors, Market Shares (%), 2013
Pharma & Biotech
19.1%
Technology
16.4%
Automobile
15.6% Software &
Computer
8.6%
Industrial
Engineering
4.7%
Aerospace &
Defence
3.3%
Chemicals
2.9%
Source: visiongain 2014, IFPMA 2013

10. www.visiongain.com Page 46
Cell-Based Assays: World Industry
and Market Prospects 2014-2024
ageing populations and increasing wealth. The second half of the forecast period should see an
improved growth rate, yet the market is expected to remain stable overall. Investment in
pharmaceutical R&D is expected to gradually grow as a result of improved global economic
conditions. This will provide greater funding for early biopharmaceutical research. Leading pharma
companies will seek to invest heavily in R&D again, following a period of cost cutting caused by
revenue loss from patent expiries and recent industry M&A activity. By 2024, visiongain anticipates
the total pharma R&D expenditure will amount to $127.92bn, with a 6-year CAGR of 2.5%.
Table 3.10 Pharma Global R&D Spending: Revenue Forecast ($bn, AGR %,
CAGR %), 2013-2024
2013 2014 2015 2016 2017 2018
Revenues ($bn) 102.91 103.94 104.98 107.08 109.22 110.31
AGR (%) 1 1 2 2 1
CAGR (%) 1.4
2019 2020 2021 2022 2023 2024
Revenues ($bn) 112.52 115.89 119.37 122.95 125.41 127.92
AGR (%) 2 3 3 3 2 2
CAGR (%) 2.5
Figure 3.11 Pharma Global R&D Spending, Revenue Forecast ($bn), 2013-2024
0.00
20.00
40.00
60.00
80.00
100.00
120.00
140.00
2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Revenues($bn)
Year
Source: visiongain 2014; CAGR values for year ranges 2013-2018 and 2018-2024
Source: visiongain 2014